WEBULL
WebtradeDownload

European Penny Stocks: Polygiene Group And 2 More Companies To Watch

Simply Wall St · 2d ago

The European markets have recently experienced volatility, influenced by renewed Middle East tensions and a more hawkish stance from the European Central Bank. Amidst these fluctuations, investors are exploring diverse opportunities, including penny stocks. Although considered a niche investment area today, penny stocks—typically representing smaller or newer companies—can still offer significant growth potential when backed by strong financial health and solid fundamentals.

Here we highlight a subset of our preferred stocks from the screener.

Polygiene Group (OM:POLYG)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Polygiene Group AB offers antimicrobial technologies for textiles and hard surfaces across multiple regions including Asia Pacific, Europe, the Middle East, Africa, and the United States, with a market cap of SEK131.50 million.

Operations: The company generates revenue from its Addmaster segment at SEK74.25 million and its Polygiene segment at SEK87.50 million.

Market Cap: SEK131.5M

Polygiene Group AB, with a market cap of SEK131.50 million, operates in the antimicrobial technologies sector and has shown some financial improvement despite being unprofitable. The company reported a net income of SEK 0.439 million for Q2 2026, compared to a significant loss the previous year, indicating progress in its earnings trajectory. Polygiene remains debt-free and maintains sufficient cash runway for over three years due to positive free cash flow. However, its share price has been highly volatile recently, and management's relatively short tenure suggests potential instability in leadership experience.

OM:POLYG Financial Position Analysis as at Oct 2026
OM:POLYG Financial Position Analysis as at Oct 2026

Equnico (WSE:EQU)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Equnico SE operates in the construction industry across Poland, Uzbekistan, and Central and Eastern Europe with a market capitalization of PLN474.82 million.

Operations: Equnico SE has not reported any revenue segments.

Market Cap: PLN474.82M

Equnico SE, with a market cap of PLN474.82 million, operates in the construction industry across Central and Eastern Europe. The company reported sales of PLN67.2 million for the half year ending June 30, 2026, showing growth from PLN39.06 million a year earlier; however, net income declined to PLN0.416 million from PLN2.5 million previously due to large one-off gains impacting past earnings results. Despite this, Equnico's earnings growth of 77.5% over the past year surpasses industry averages and its debt levels have decreased significantly over five years while maintaining adequate short-term asset coverage for liabilities.

WSE:EQU Revenue & Expenses Breakdown as at Oct 2026
WSE:EQU Revenue & Expenses Breakdown as at Oct 2026

MedTech Solutions (WSE:MDT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: MedTech Solutions S.A. focuses on the research, development, and distribution of medical and diagnostic products, with a market cap of PLN28.54 million.

Operations: MedTech Solutions S.A. has not reported any specific revenue segments.

Market Cap: PLN28.54M

MedTech Solutions S.A., with a market cap of PLN28.54 million, operates in the medical and diagnostic products sector and remains pre-revenue, reporting less than US$1 million in revenues. Despite having no debt and short-term assets of PLN4 million exceeding liabilities, its financial position is strained by a cash runway of less than a year. The company is unprofitable with losses increasing over five years at 26.4% annually. Recent earnings showed improvement with reduced net losses compared to last year, but volatility remains high and the board's average tenure suggests limited experience at 1.5 years.

WSE:MDT Debt to Equity History and Analysis as at Oct 2026
WSE:MDT Debt to Equity History and Analysis as at Oct 2026

Key Takeaways

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.